APA (7th ed.) Citation

WA, E., A, G., N, B. H., AR, S., AAM, E., HS, H., . . . SA, H. (2026). Development of a multi-targeted sulfonyl-bridged bisselenadiazole derivative as a potent EGFR/PI3K/AKT/mTOR modulator in lung adenocarcinoma. RSC advances, 16(22), 19903. https://doi.org/10.1039/d6ra02006b

Chicago Style (17th ed.) Citation

WA, El-Fattah, Guesmi A, Ben Hamadi N, Sayed AR, El-Reedy AAM, Hafez HS, Elshaarawy RFM, and Hassan SA. "Development of a Multi-targeted Sulfonyl-bridged Bisselenadiazole Derivative as a Potent EGFR/PI3K/AKT/mTOR Modulator in Lung Adenocarcinoma." RSC Advances 16, no. 22 (2026): 19903. https://doi.org/10.1039/d6ra02006b.

MLA (9th ed.) Citation

WA, El-Fattah, et al. "Development of a Multi-targeted Sulfonyl-bridged Bisselenadiazole Derivative as a Potent EGFR/PI3K/AKT/mTOR Modulator in Lung Adenocarcinoma." RSC Advances, vol. 16, no. 22, 2026, p. 19903, https://doi.org/10.1039/d6ra02006b.